These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35185467)

  • 21. Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease.
    Doria JG; Silva FR; de Souza JM; Vieira LB; Carvalho TG; Reis HJ; Pereira GS; Dobransky T; Ribeiro FM
    Br J Pharmacol; 2013 Jun; 169(4):909-21. PubMed ID: 23489026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The mGluR5 positive allosteric modulator VU0409551 improves synaptic plasticity and memory of a mouse model of Huntington's disease.
    Doria JG; de Souza JM; Silva FR; Olmo IG; Carvalho TG; Alves-Silva J; Ferreira-Vieira TH; Santos JT; Xavier CQS; Silva NC; Maciel EMA; Conn PJ; Ribeiro FM
    J Neurochem; 2018 Oct; 147(2):222-239. PubMed ID: 30028018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of Drp1 hyperactivation reduces neuropathology and behavioral deficits in zQ175 knock-in mouse model of Huntington's disease.
    Zhao Y; Sun X; Qi X
    Biochem Biophys Res Commun; 2018 Dec; 507(1-4):319-323. PubMed ID: 30449600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative Electroencephalographic Analysis Provides an Early-Stage Indicator of Disease Onset and Progression in the zQ175 Knock-In Mouse Model of Huntington's Disease.
    Fisher SP; Schwartz MD; Wurts-Black S; Thomas AM; Chen TM; Miller MA; Palmerston JB; Kilduff TS; Morairty SR
    Sleep; 2016 Feb; 39(2):379-91. PubMed ID: 26446107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease.
    Schiefer J; Sprünken A; Puls C; Lüesse HG; Milkereit A; Milkereit E; Johann V; Kosinski CM
    Brain Res; 2004 Sep; 1019(1-2):246-54. PubMed ID: 15306259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Striatal spatial heterogeneity, clustering, and white matter association of GFAP
    Brown TG; Thayer MN; VanTreeck JG; Zarate N; Hart DW; Heilbronner S; Gomez-Pastor R
    Front Cell Neurosci; 2023; 17():1094503. PubMed ID: 37187609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SorCS2-mediated NR2A trafficking regulates motor deficits in Huntington's disease.
    Ma Q; Yang J; Milner TA; Vonsattel JG; Palko ME; Tessarollo L; Hempstead BL
    JCI Insight; 2017 May; 2(9):. PubMed ID: 28469074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Huntington's disease and Group I metabotropic glutamate receptors.
    Ribeiro FM; Pires RG; Ferguson SS
    Mol Neurobiol; 2011 Feb; 43(1):1-11. PubMed ID: 21153060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabotropic glutamate receptor-mediated cell signaling pathways are altered in a mouse model of Huntington's disease.
    Ribeiro FM; Paquet M; Ferreira LT; Cregan T; Swan P; Cregan SP; Ferguson SS
    J Neurosci; 2010 Jan; 30(1):316-24. PubMed ID: 20053912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abnormal Brain Development in Huntington' Disease Is Recapitulated in the zQ175 Knock-In Mouse Model.
    Zhang C; Wu Q; Liu H; Cheng L; Hou Z; Mori S; Hua J; Ross CA; Zhang J; Nopoulos PC; Duan W
    Cereb Cortex Commun; 2020; 1(1):tgaa044. PubMed ID: 32984817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Small, Seeding-Competent Huntingtin Fibrils Are Prominent Aggregate Species in Brains of zQ175 Huntington's Disease Knock-in Mice.
    Schindler F; Praedel N; Neuendorf N; Kunz S; Schnoegl S; Mason MA; Taxy BA; Bates GP; Khoshnan A; Priller J; Grimm J; Maier M; Boeddrich A; Wanker EE
    Front Neurosci; 2021; 15():682172. PubMed ID: 34239412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss-of-Huntingtin in Medial and Lateral Ganglionic Lineages Differentially Disrupts Regional Interneuron and Projection Neuron Subtypes and Promotes Huntington's Disease-Associated Behavioral, Cellular, and Pathological Hallmarks.
    Mehler MF; Petronglo JR; Arteaga-Bracho EE; Gulinello ME; Winchester ML; Pichamoorthy N; Young SK; DeJesus CD; Ishtiaq H; Gokhan S; Molero AE
    J Neurosci; 2019 Mar; 39(10):1892-1909. PubMed ID: 30626701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease.
    Dai Y; Dudek NL; Li Q; Fowler SC; Muma NA
    J Neurosci; 2009 Sep; 29(37):11550-9. PubMed ID: 19759302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal Small-Animal PET Imaging of the zQ175 Mouse Model of Huntington Disease Shows In Vivo Changes of Molecular Targets in the Striatum and Cerebral Cortex.
    Häggkvist J; Tóth M; Tari L; Varnäs K; Svedberg M; Forsberg A; Nag S; Dominguez C; Munoz-Sanjuan I; Bard J; Wityak J; Varrone A; Halldin C; Mrzljak L
    J Nucl Med; 2017 Apr; 58(4):617-622. PubMed ID: 27856625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor.
    Lindemann L; Jaeschke G; Michalon A; Vieira E; Honer M; Spooren W; Porter R; Hartung T; Kolczewski S; Büttelmann B; Flament C; Diener C; Fischer C; Gatti S; Prinssen EP; Parrott N; Hoffmann G; Wettstein JG
    J Pharmacol Exp Ther; 2011 Nov; 339(2):474-86. PubMed ID: 21849627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alterations of striatal indirect pathway neurons precede motor deficits in two mouse models of Huntington's disease.
    Sebastianutto I; Cenci MA; Fieblinger T
    Neurobiol Dis; 2017 Sep; 105():117-131. PubMed ID: 28578004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
    Cho IK; Yang B; Forest C; Qian L; Chan AWS
    PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of HTT inclusion size, location, and timing in the zQ175 mouse model of Huntington's disease: an in vivo high-content imaging study.
    Carty N; Berson N; Tillack K; Thiede C; Scholz D; Kottig K; Sedaghat Y; Gabrysiak C; Yohrling G; von der Kammer H; Ebneth A; Mack V; Munoz-Sanjuan I; Kwak S
    PLoS One; 2015; 10(4):e0123527. PubMed ID: 25859666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. mGluR5 Contribution to Neuropathology in Alzheimer Mice Is Disease Stage-Dependent.
    Abd-Elrahman KS; Hamilton A; Albaker A; Ferguson SSG
    ACS Pharmacol Transl Sci; 2020 Apr; 3(2):334-344. PubMed ID: 32296772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic cannabinoid receptor stimulation selectively prevents motor impairments in a mouse model of Huntington's disease.
    Pietropaolo S; Bellocchio L; Ruiz-Calvo A; Cabanas M; Du Z; Guzmán M; Garret M; Cho YH
    Neuropharmacology; 2015 Feb; 89():368-74. PubMed ID: 25123645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.